Show simple item record

dc.contributor.authorMorris, Noreen
dc.contributor.authorMcLaughlin, Gavin
dc.contributor.authorKavanagh, Pierce V.
dc.contributor.authorPower, John D.
dc.contributor.authorDowling, Geraldine
dc.contributor.authorTwamley, Brendan
dc.contributor.authorO'Brien, Brendan
dc.contributor.authorO'Brien, John
dc.contributor.authorHessman, Gary
dc.contributor.authorMurphy, Brian
dc.contributor.authorWalther, Donna
dc.contributor.authorPartilla, John S.
dc.contributor.authorBaumann, Michael H.
dc.contributor.authorBrandt, Simon D.
dc.identifier.citationMorris, N., McLaughlin, G., Kavanagh, Pierce V., Power, J.D., Dowling, G., Twamley, B., O'Brien, J., Hessman, Murphy, B., G.,Walther, D., Partilla, J.S., Baumann, S.D., Brandt, S. D. (2017). Analytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (±)-threo- and (±)-erythro- diastereomers. Drug Testing and Analysis. 9 (3), 347-357. doi: 10.1002/dta.2167.en_US
dc.identifier.otherFaculty of Science & Health - Life and Physical - Articlesen_US
dc.description.abstractMisuse of (±)-threo-methylphenidate (methyl-2-phenyl-2-(piperidin-2-yl)acetate; Ritalin®; MPH) has long been acknowledged, but the appearance of MPH analogs in the form of 'research chemicals' has only emerged in more recent years. 4-Fluoromethylphenidate (4F-MPH) is one of these recent examples. This study presents the identification and analytical characterization of two powdered 4F-MPH products that were obtained from an online vendor in 2015. Interestingly, the products appeared to have originated from two distinct batches given that one product consisted of (±)-threo-4F-MPH isomers whereas the second sample consisted of a mixture of (±)-threo and (±)-erythro 4F-MPH. Monoamine transporter studies using rat brain synaptosomes revealed that the biological activity of the 4F-MPH mixture resided with the (±)-threo and not the (±)-erythro isomers based on higher potencies determined for blockage of dopamine uptake (IC50 4F-MPHmixture = 66 nM vs. IC50 (±)-threo = 61 nM vs. IC50 (±)-erythro = 8,528 nM) and norepinephrine uptake (IC50 4F-MPHmixture = 45 nM vs. (±)-threo = 31 nM vs. IC50 (±)-erythro = 3,779 nM). In comparison, MPH was three times less potent than (±)-threo-4F-MPH at the dopamine transporter (IC50 = 131 nM) and around 2.5 times less potent at the norepinephrine transporter (IC50 = 83 nM). Both substances were catecholamine selective with IC50 values of 8,805 nM and >10,000 nM for (±)-threo-4F-MPH and MPH at the serotonin transporter. These findings suggest that the psychostimulant properties of (±)-threo-4F-MPH might be more potent in humans than MPH.en_US
dc.relation.ispartofDrug Testing and Analysisen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Ireland*
dc.subjectPsychoactive substancesen_US
dc.titleAnalytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (±)-threo- and (±)-erythro- diastereomersen_US
dc.rights.accessOpen Accessen_US
dc.subject.departmentFaculty of Science and Healthen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Ireland
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland